These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 29702784)

  • 21. Developing drug formularies for the "National Medical Holding" JSC.
    Akhmadyar NS; Khairulin BE; Amangeldy-Kyzy S; Ospanov MA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S51-2. PubMed ID: 26639709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What technologies for health care in developing countries?
    Perry S; Marx ES
    World Health Forum; 1992; 13(4):356-62. PubMed ID: 1466744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The uses of modern technologies: problems and perspectives for industrialized and developing countries.
    Banta D
    Bull Pan Am Health Organ; 1984; 18(2):139-50. PubMed ID: 6487871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
    Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
    Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
    Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
    Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Involving patients in the evaluation of health technologies at the French National Authority for Health (HAS)].
    Nabarette H
    Sante Publique; 2018; 30(6):767-775. PubMed ID: 30990265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of the decisions of the Israeli Public Committee for updating the National List of Health Services in 2006/2007.
    Shmueli A
    Value Health; 2009; 12(2):202-6. PubMed ID: 18657095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Specific proposals for organising an agency for evaluating the efficiency of health technologies and policies].
    Lobo F; Oliva J; Vida J
    Gac Sanit; 2024 Aug; 38():102417. PubMed ID: 39094385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of the recommendations issued by the National Commission for the Incorporation of Technologies in SUS after Public Consultations.
    Lopes SGP; Luiza VL; Silva RMD
    Cien Saude Colet; 2023 Feb; 28(2):561-573. PubMed ID: 36651407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technology Assessment at the National Level in the US.
    Cotter DJ; Perry S; Thamer M
    Surg Technol Int; 1999; 8():45-8. PubMed ID: 12451508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technology assessment.
    Brevis JS
    Surg Technol Int; 1996; 5():56-60. PubMed ID: 15858717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Constitutional thoughts on the Mexican General Health Council].
    Cossío Díaz JR; Goslinga Remírez L; Mejía Garza RM; Montes de Oca Arboleya R
    Gac Med Mex; 2013; 149(3):356-62. PubMed ID: 23807340
    [No Abstract]   [Full Text] [Related]  

  • 36. A framework for explaining the role of values in health policy decision-making in Latin America: a critical interpretive synthesis.
    Vélez CM; Wilson MG; Lavis JN; Abelson J; Florez ID
    Health Res Policy Syst; 2020 Sep; 18(1):100. PubMed ID: 32894131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Relationship Between Spatial Distribution of Medical Equipment and Preventable Mortality.
    Gavurova B; Tucek D; Kovac V
    Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31416229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Update of the Mexican Health Care Formulary and Supply Catalog in the Context of the Health Technology Assessment.
    Ríos PR; Rivera AG; Oropeza IR; Ramírez OC
    Value Health Reg Issues; 2014 Dec; 5():29-34. PubMed ID: 29702784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Criterios Farmacoeconómicos Usados en México para la Evaluación de Tratamientos en Personas en Fases Terminales.
    Rizo Ríos P; González Rivera A; Campos Ramírez O; Lifshitz Guinzberg A
    Value Health Reg Issues; 2012 Dec; 1(2):264-266. PubMed ID: 29702912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Not Available].
    Ríos PR; Rivera AG; Oropeza IR; Rivas Bocanegra RE
    Value Health Reg Issues; 2013 Dec; 2(3):387-391. PubMed ID: 29702775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.